Spinal Cord Stimulation Devices Market
Spinal Cord Stimulation Devices Market
$4,750.00
The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies.
Publisher: MedTech Insight
- Description
- Contents
- Samples
This analysis includes a discussion of current Spinal Cord Stimulation (SCS) devices, emerging innovative technologies, competitors, trends, and expected market growth. Market analysis includes a 5-year market forecast by region, drivers/limiters, estimated market share by region, and corporate strategies for success in one of the fastest medical device markets today.
KEY QUESTIONS ANSWERED
- What is the value of the global SCS devices market? What is the expected growth over the next 5 years?
- What is the expected market growth by major region of the world (US, 5EU, Japan, and RoW)?
- What are the key drivers & limiters?
- Technological trends?
- Who are the leading competitors, estimated market share by region, and strategic growth strategies?
REPORT HIGHLIGHTS
- The global SCS devices market was valued at more than $2.5bn in 2017 and is expected to grow at a double-digit CAGR of more than 13% over the next 5 years.
- The US remains the largest SCS market, accounting for more than 75% of the total market in 2017, although regions outside the US such as the 5EU represent good growth potential.
- The market will be driven by several factors, including the aging population and corresponding increase in diseases/injuries/trauma resulting in chronic, intractable pain (eg back/leg pain), solid clinical history, technological innovation, and growing awareness and usage of SCS technologies.
- Technological trends and innovations include but are not limited to: expanding pain indications (eg to peripheral nerve targets), customizing and broadening pain coverage and precision, miniaturization/less invasive device technologies, elimination of paresthesia, lowering overall risk profile, improving ease of use/implantation, greater patient monitoring/tracking, and providing even higher, sustained pain relief. A future goal of SCS is eliminating surgery altogether.
Table of Contents
Executive Summary………………………………………………………………………………………………….. ES-1
i. Report overview……………………………………………………………………………………………….ES-1
ii. Chronic intractable pain…………………………………………………………………………………….ES-1
iii. SCS devices………………………………………………………………………………………………………ES-2
iv. SCS devices market……………………………………………………………………………………………ES-3
a. Market drivers and limiters………………………………………………………………………………..ES-6
b. Technology trends…………………………………………………………………………………………….ES-8
c. Market share ……………………………………………………………………………………………………ES-8
v. Methodology ………………………………………………………………………………………………….ES-10
vi. Bibliography……………………………………………………………………………………………………ES-12
Exhibit ES-1: Selected types of chronic pain, estimated US prevalence……………………………………..ES-2
Exhibit ES-2: Spinal cord stimulation devices, global market forecast ($m), 2017-22 ………………….ES-4
Exhibit ES-3: Spinal cord stimulation devices market, estimated share of revenues by region, 2017 ……………………………………………………………………………………………….ES-5
Exhibit ES-4: Spinal cord stimulation devices market, estimated global share by supplier, 2017 ………………………………………………………………………………………………………………ES-8
1. Clinical Overview…………………………………………………………………………………………………….1-1
1.1 Chronic pain ……………………………………………………………………………………………………… 1-1
1.2 Spinal cord, nerves, and the transmission of pain………………………………………………….. 1-2
1.3 The central nervous system versus peripheral nervous system……………………………….. 1-4
1.4 Pain statistics ……………………………………………………………………………………………………. 1-5
1.5 Cost of pain ………………………………………………………………………………………………………. 1-7
1.6 Pain treatment………………………………………………………………………………………………….. 1-7
1.7 Opioid abuse and deaths……………………………………………………………………………………. 1-7
1.8 Procedural therapies for treating pain …………………………………………………………………. 1-9
1.9 Spinal cord stimulation …………………………………………………………………………………….. 1-10
1.10 Peripheral nerve stimulation …………………………………………………………………………… 1-12
1.11 Transcutaneous electrical nerve stimulation……………………………………………………… 1-13
1.12 Bibliography ………………………………………………………………………………………………….. 1-14
Exhibit 1-1: Diagram of the spine and spinal cord…………………………………………………………………… 1-3
Exhibit 1-2: The nervous system, including four types of nerves………………………………………………. 1-4
Exhibit 1-3: Selected types of chronic pain, estimated US prevalence……………………………………….. 1-6
Exhibit 1-4: The US opioid epidemic by numbers, 2016…………………………………………………………… 1-8
Exhibit 1-5: Diagram of cardiac pacemaker implantation ………………………………………………………. 1-11
Exhibit 1-6: Basic diagram of SCS system implantation………………………………………………………….. 1-11
2. Neuromodulation Technologies for the Treatment of Pain ……………………………………………..2-1
2.1 Spinal cord stimulation systems ………………………………………………………………………….. 2-1
2.1.1 Abbott (St. Jude Medical) …………………………………………………………………….. 2-8
2.1.2 Boston Scientific………………………………………………………………………………… 2-11
2.1.3 Medtronic ………………………………………………………………………………………… 2-15
2.1.4 Nevro ………………………………………………………………………………………………. 2-18
2.1.5 Nuvectra…………………………………………………………………………………………… 2-20
2.1.6 Saluda Medical………………………………………………………………………………….. 2-21
2.1.7 Stimwave………………………………………………………………………………………….. 2-24
2.2 Emerging minimally invasive pain stimulation systems…………………………………………. 2-27
2.2.1 Autonomic Technologies ……………………………………………………………………. 2-28
2.2.2 Bioness…………………………………………………………………………………………….. 2-30
2.2.3 electroCore ………………………………………………………………………………………. 2-33
2.2.4 Mainstay Medical………………………………………………………………………………. 2-35
2.2.5 NeuroMetrix …………………………………………………………………………………….. 2-36
2.2.6 Neuros Medical…………………………………………………………………………………. 2-39
2.2.7 SPR Therapeutics ………………………………………………………………………………. 2-40
2.3 Clinical trial results: spinal cord stimulation………………………………………………………… 2-42
2.3.1 Abbott/SUNBURST study ……………………………………………………………………. 2-43
2.3.2 Abbott/TRIUMPH study ……………………………………………………………………… 2-44
2.3.3 Boston Scientific/WHISPER study ………………………………………………………… 2-44
2.3.4 Nevro/SENZA-RCT study …………………………………………………………………….. 2-45
2.3.5 Medtronic/VECTORS study …………………………………………………………………. 2-47
2.4 Technological trends………………………………………………………………………………………… 2-48
2.5 Primary research: SCS pain questionnaire to physicians……………………………………….. 2-49
2.6 Primary research: KOL Insight Interview……………………………………………………………… 2-53
2.7 Medtronic SCS product performance questionnaire…………………………………………….. 2-55
2.8 Reimbursement ………………………………………………………………………………………………. 2-56
2.9 Risks ………………………………………………………………………………………………………………. 2-57
2.10 Bibliography ………………………………………………………………………………………………….. 2-59
Exhibit 2-1: Selected leading spinal cord stimulation systems……………………………………………. 2-3
Exhibit 2-2: New/recently approved spinal cord stimulation and peripheral nerve stimulation devices, 2017-18 …………………………………………………………………………………………. 2-7
Exhibit 2-3: BurstDR stimulation pain relief……………………………………………………………………… 2-9
Exhibit 2-4: St. Jude Medical Invisible Trial System …………………………………………………………. 2-10
Exhibit 2-5: Boston Scientific’s new Spectra WaveWriter SCS System……………………………….. 2-13
Exhibit 2-6: Boston Scientific’s original Precision Spectra System, designed with 32 contacts and 32 dedicated power sources……………………………………………………. 2-15
Exhibit 2-7: Medtronic’s new Intellis SCS platform………………………………………………………….. 2-16
Exhibit 2-8: Nevro’s Senza SCS system…………………………………………………………………………… 2-19
Exhibit 2-9: Nuvectra’s Algovita SCS system…………………………………………………………………… 2-21
Exhibit 2-10: Saluda Medical’s innovative closed-loop Evoke SCS System……………………………. 2-22
Exhibit 2-11: Stimwave’s Freedom SCS system…………………………………………………………………. 2-26
Exhibit 2-12: Selected new or emerging PNS/TENS devices……………………………………………….. 2-28
Exhibit 2-13: ATI Neurostimulator System for treating cluster headache…………………………….. 2-29
Exhibit 2-14: Bioness’s StimRouter system for treating peripheral nerve pain……………………… 2-32
Exhibit 2-15: electroCore’s externally applied gammaCore system for treating chronic migraine and cluster headache………………………………………………………… 2-33
Exhibit 2-16: Mainstay Medical’s ReActiv8 system……………………………………………………………. 2-35
Exhibit 2-17: NeuroMetrix’s high-power, proprietary wearable Quell device for chronic pain relief ……………………………………………………………………………………… 2-37
Exhibit 2-18: Neuros Medical’s implantable Altius system for peripheral nerve stimulation….. 2-40
Exhibit 2-19: SPR Therapeutics’ SPRINT PNS system …………………………………………………………. 2-41
3. Spinal Cord Stimulation Devices Market………………………………………………………………………3-1
3.1 Market forecast: global………………………………………………………………………………………. 3-1
3.1.1 Market forecast: US……………………………………………………………………. 3-4
3.1.2 Market forecast: five major EU markets……………………………………….. 3-5
3.1.3 Market forecast: Japan……………………………………………………………….. 3-5
3.1.4 Market forecast: RoW………………………………………………………………… 3-5
3.1.5 Market drivers and limiters…………………………………………………………. 3-6
3.2 Competitive analysis………………………………………………………………………………………….. 3-8
3.2.1 Market share: global ………………………………………………………………….. 3-8
3.2.2 Market share: by region……………………………………………………………. 3-11
3.3 Corporate profiles……………………………………………………………………………………………. 3-11
3.3.1 Abbott…………………………………………………………………………………….. 3-11
3.3.2 Boston Scientific………………………………………………………………………. 3-13
3.3.2 Medtronic……………………………………………………………………………….. 3-14
3.3.3 Nevro……………………………………………………………………………………… 3-17
3.3.4 Nuvectra…………………………………………………………………………………. 3-19
3.4 Bibliography ……………………………………………………………………………………………………. 3-23
Exhibit 3-1: Spinal cord stimulation devices, global market forecast ($m), 2017-22 ……………………. 3-1
Exhibit 3-2: Spinal cord stimulation devices market, estimated share of revenues by region, 2017…………………………………………………………………………………………………. 3-3
Exhibit 3-3: Spinal cord stimulation devices market, forecast sales by region ($m), 2017-22……….. 3-3
Exhibit 3-4: Spinal cord stimulation devices market, estimated global share by supplier, 2017 ……. 3-9
Exhibit 3-5: Spinal cord stimulation devices market, estimated share by supplier and region, 2017……………………………………………………………………………………………… 3-11
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement 
Sign up to the